This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
National Collaborating Centre for Mental Health (UK). Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update). National Institute for Health and Clinical Excellence (NICE) Clinical Guidelines. No. 82. Leicester: British Psychological Society; 2009: 1-399.National Collaborating Centre for Mental Health (UK)Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update)National Institute for Health and Clinical Excellence (NICE) Clinical GuidelinesNo. 82LeicesterBritish Psychological Society20091399Search in Google Scholar
WHO. World Health Organization International Classification of Diseases, 10th ed. Geneva: WHO; 1990.WHOWorld Health Organization International Classification of Diseases10thGenevaWHO1990Search in Google Scholar
Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2:el41.SahaSChantDWelhamJMcGrathJA systematic review of the prevalence of schizophreniaPLoS Med20052el4110.1371/journal.pmed.0020141114095215916472Search in Google Scholar
Years of lives with disability from mental disorders. Thailand 2004. Thailand International Health Policy Program. Nonthaburi: Ministry of Public Health; 2004. pp. 21. [Online] 2005 [cited 2015 October 30] Available from: www.thaibod.net/documents/YLD%20Mental%20disorders.pdfYears of lives with disability from mental disorders, Thailand2004Thailand International Health Policy ProgramNonthaburiMinistry of Public Health200421[Online] 2005 [cited 2015 October 30] Available fromwww.thaibod.net/documents/YLD%20Mental%20disorders.pdfSearch in Google Scholar
Phanthunane P, Vos T, Whiteford H, Bertram M, Udomratn P. Schizophrenia in Thailand: prevalence and burden of disease. Popul Health Metr. 2010; 8: 24.2071290910.1186/1478-7954-8-24PhanthunanePVosTWhitefordHBertramMUdomratnPSchizophrenia in Thailand: prevalence and burden of diseasePopul Health Metr2010824293627820712909Search in Google Scholar
Tandon RT, Targum SD, Nasrallah HA, Ross R; Treatment Effectiveness in Schizophrenia Consortium. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. J Psychiatr Prac. 2006; 12: 348-63.TandonRTTargumSDNasrallahHARossRTreatment Effectiveness in Schizophrenia ConsortiumStrategies for maximizing clinical effectiveness in the treatment of schizophrenia. J Psychiatr Prac2006123486310.1097/00131746-200611000-0000317122696Search in Google Scholar
Janicak PG, Davis JM, Preskorn SH, Ayd FJ. Principles and practice of psychopharmacotherapy. Baltimore: Williams and Wilkins; 1993, pp. 592.JanicakPGDavisJMPreskornSHAydFJPrinciples and practice of psychopharmacotherapyBaltimoreWilliams and Wilkins1993592Search in Google Scholar
Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence: incidence: and risk factors. Psychopharmacology. 1985; 2:72-8.KaneJMWoernerMLiebermanJTardive dyskinesia: prevalence: incidence: and risk factorsPsychopharmacology1985272810.1097/00004714-198808001-000103220968Search in Google Scholar
Suvisaari JM, Saarni SI, Perala J, Suvisaari JV, Harkanen T, Lonnqvist J, et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry. 2007; 68:1045-55.10.4088/JCP.v68n0711SuvisaariJMSaarniSIPeralaJSuvisaariJVHarkanenTLonnqvistJet alMetabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population surveyJ Clin Psychiatry20076810455517685741Open DOISearch in Google Scholar
Meaney AM, O’Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophrenia Res. 2007; 93: 13643.10.1016/j.schres.2007.01.013MeaneyAMO’KeaneVBone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variablesSchizophrenia Res2007931364317467954Open DOISearch in Google Scholar
Disyavanish C, Srisurapanont M, Karnjanathanalers N, Theeramoke V, KongsakonR, Kittiratanapaibool P, et al. Thai schizophrenia treatment guidelines. In: Sukanit P, Udomrath P, editors. Clinical practice guidelines in psychiatric disorders. Bangkok: Beyond Enterprise; 2001: p. 67-90.DisyavanishCSrisurapanontMKarnjanathanalersNTheeramokeVKongsakonRKittiratanapaiboolPet alThai schizophrenia treatment guidelinesSukanitPUdomrathPClinical practice guidelines in psychiatric disordersBangkokBeyond Enterprise20016790Search in Google Scholar
LamY-WF, Velligan DI, Ereshefsky L. Intra-individual variability in plasma concentrations as an indicator of adherence in schizophrenia [abstract]. Poster presented at the 42nd Annual Meeting of New Clinical Drug Evaluation Unit (NCDEU) June 10-13, 2002; Boca Raton, FL, USA.LamY-WFVelliganDIEreshefskyLIntra-individual variability in plasma concentrations as an indicator of adherence in schizophrenia [abstract]Poster presented at the 42nd Annual Meeting of New Clinical Drug Evaluation Unit (NCDEU)June10132002Boca RatonFL, USASearch in Google Scholar
Weiden P, Glazer W. Assessment and treatment selection for O“revolving doorO” inpatients with schizophrenia. PsychiatrQ. 1997; 68:377-92.WeidenPGlazerWAssessment and treatment selection for O“revolving doorO” inpatients with schizophreniaPsychiatrQ19976837792Search in Google Scholar
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med. 2005; 353:1209-23.10.1056/NEJMoa051688LiebermanJAStroupTSMcEvoyJPSwartzMSRosenheckRAPerkinsDOet alEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Eng J Med200535312092316172203Open DOISearch in Google Scholar
Kane JM. Treatment adherence and long-term outcomes. CNS Spectrums. 2007; 12:21-6.10.1017/S109285290002630417934386KaneJMTreatment adherence and long-term outcomesCNS Spectrums200712216Open DOISearch in Google Scholar
Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008; 8:32.1844793510.1186/1471-244X-8-32MorkenGWidenJHGraweRWNon-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophreniaBMC Psychiatry2008832239055018447935Search in Google Scholar
Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105-24.1544933810.1002/sim.1875LuGAdesAECombination of direct and indirect evidence in mixed treatment comparisonsStat Med20042331052415449338Search in Google Scholar
Jansen JP, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008; 11:956-64.1848949910.1111/j.1524-4733.2008.00347.xJansenJPCrawfordBBergmanGStamWBayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisonsValue Health20081195664Search in Google Scholar
Leucht S, Cipriani A, Spineli L, Mavridis D, rey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 ; 3 82:951-62.2381001910.1016/S0140-6736(13)60733-3LeuchtSCiprianiASpineliLMavridisDreyDRichterFet alComparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisLancet201338295162Search in Google Scholar
Ades AE, Mavranezouli I, Dias S, Welton NJ, Whittington C, Kendall T. Network meta-analysis with competing risk outcomes. Value Health. 2010; 13 : 976-83.10.1111/j.1524-4733.2010.00784.x20825617AdesAEMavranezouliIDiasSWeltonNJWhittingtonCKendallTNetwork meta-analysis with competing risk outcomesValue Health20101397683Open DOISearch in Google Scholar
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17:1-12.10.1016/0197-2456(95)00134-48721797JadadARMooreRACarrollDJenkinsonCReynoldsDJGavaghanDJet alAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials199617112Open DOISearch in Google Scholar
Dias S, Welton NJ, Sutton AJ, Ades A. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. [On line]. 2011 [last updated April 2012; cited 2015 October 31]. 2011; 20111893, Available from www.nicedsu.org.ukresearch-information.bristol.ac.uk/files/7215331TSD2_General_meta_analysis.final.08.05.12.pdfDiasSWeltonNJSuttonAJAdesANICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials[On line]. 2011 [last updated April 2012; cited 2015 October 31]201120111893www.nicedsu.org.ukresearch-information.bristol.ac.uk/files/7215331TSD2_General_meta_analysis.final.08.05.12.pdfSearch in Google Scholar
Welton NJ, Sutton AJ, Cooper N, Abrams KR, Ades AE. Evidence synthesis for decision making in healthcare. Statistics in Practice (series), volume 126. Hoboken: Wiley; 2012.WeltonNJSuttonAJCooperNAbramsKRAdesAEEvidence synthesis for decision making in healthcareStatistics in Practice (series)126HobokenWiley201210.1002/9781119942986Search in Google Scholar
Hirsch SR, Gaind R, Rohde PD, Stevens BC, Wing JK. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial, report to the Medical Research Council Committee on Clinical Trials in Psychiatry. BMJ. 1973; 1:633-7.10.1136/bmj.1.5854.633HirschSRGaindRRohdePDStevensBCWingJKOutpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial, report to the Medical Research Council Committee on Clinical Trials in PsychiatryBMJ19731633715886394571196Open DOISearch in Google Scholar
Odejide OA, Aderounmu AF. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. J Clin Psychiatry. 1982; 43: 195-6.7076630OdejideOAAderounmuAFDouble-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patientsJ Clin Psychiatry1982431956Search in Google Scholar
Sampath G, Shah A, Krska J, Soni SD. Neuroleptic discontinuation in the very stable schizophrenic patient: Relapse rates and serum neuroleptic levels. Hum Psychopharmacol. 1992;7:255-64.10.1002/hup.470070405SampathGShahAKrskaJSoniSDNeuroleptic discontinuation in the very stable schizophrenic patient: Relapse rates and serum neuroleptic levelsHum Psychopharmacol1992725564Open DOISearch in Google Scholar
Eberhard G, Hellbom E. Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison. Acta Psychiatr Scand 1986; 74:255-62.EberhardGHellbomEHaloperidol decanoate and flupenthixol decanoate in schizophreniaA long-term double-blind cross-over comparison. Acta Psychiatr Scand1986742556210.1111/j.1600-0447.1986.tb06242.x3788652Search in Google Scholar
Chouinard G, Annable L, Campbell W. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. J Clin Psychopharmacol. 1989;9:247-53.2570086ChouinardGAnnableLCampbellWA randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophreniaJ Clin Psychopharmacol198992475310.1097/00004714-198908000-00003Search in Google Scholar
Chouinard G, Annable L, Campbell W, Boisvert D, Bradwejn J. A double-blind controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. In: Pichot P, editor. Psychiatry: the state of the art. Proceedings of the 7th World Congress of Psychiatry, held July 11-16,1983, in Vienna, Austria, 3rdEdition New York: PlenumPress; 1985, p. 759-61.ChouinardGAnnableLCampbellWBoisvertDBradwejnJA double-blind controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophreniaPichotPPsychiatry: the state of the art. Proceedings of the 7th World Congress of Psychiatry, held July 11-16,1983, in Vienna, Austria3rdNew YorkPlenumPress19857596110.1007/978-1-4613-2363-1_118Search in Google Scholar
Cookson JC, Kennedy NM, Gribbon D. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate. Int Clin Psychopharmacol. 1986; l(Suppl. 1):41-51.3549879CooksonJCKennedyNMGribbonDWeight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoateInt Clin Psychopharmacol19861Suppl. 14151Search in Google Scholar
Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ. 1990;301:837-42.228242110.1136/bmj.301.6756.837JolleyAGHirschSRMorrisonEMcRinkAWilsonLTrial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two yearsBMJ199030183742Search in Google Scholar
Jolley AG, Hirsch SR, McRink A, Manchanda R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ. 1989;298:985-90.10.1136/bmj.298.6679.9852567190JolleyAGHirschSRMcRinkAManchandaRTrial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one yearBMJ198929898590Open DOISearch in Google Scholar
Kissling W, Moller HJ, Walter K, Wittmann B, Krueger R, Trenk D. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months’ treatment for relapse prevention. Pharmacopsychiatry. 1985; 18:240-5.10.1055/s-2007-10173734011672KisslingWMollerHJWalterKWittmannBKruegerRTrenkDDouble-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months’ treatment for relapse preventionPharmacopsychiatry1985182405Open DOISearch in Google Scholar
McKane JP, Robinson AD, Wiles DH, McCreadie RG, Stirling GS. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. Br J Psychiatry. 1987; 151: 333-6.332246710.1192/bjp.151.3.333McKaneJPRobinsonADWilesDHMcCreadieRGStirlingGSHaloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patientsBr J Psychiatry19871513336Search in Google Scholar
Sharma SK, Jaigirdar SH. A comparison of fluphenazine decanoate and haloperidol decanoate in chronic schizophrenia. Br J ClinRes. 1991; 2:177-86.SharmaSKJaigirdarSHA comparison of fluphenazine decanoate and haloperidol decanoate in chronic schizophreniaBr J ClinRes1991217786Search in Google Scholar
Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol. 2012; 15:107-18.2177750710.1017/S1461145711001076FleischhackerWWGopalSLaneRGassmann-MayerCLimPHoughDet alA randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophreniaInt J Neuropsychopharmacol20121510718Search in Google Scholar
Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010; 116: 107-17.1995933910.1016/j.schres.2009.10.026HoughDGopalSVijapurkarULimPMorozovaMEerdekensMPaliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled studySchizophr Res201011610717Search in Google Scholar
Pinto R, Bannerjee A, Ghosh N. A double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Acta Psychiat Scand. 1979;60:313-22.10.1111/j.1600-0447.1979.tb00281.xPintoRBannerjeeAGhoshNA double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophreniaActa Psychiat Scand19796031322Open DOISearch in Google Scholar
Wistedt B, Ranta J. Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology. Acta Psychiat Scand. 1983; 67: 378-88.10.1111/j.1600-0447.1983.tb09718.xWistedtBRantaJComparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatologyActa Psychiat Scand19836737888Open DOISearch in Google Scholar
Wistedt B, Koskinen T, Thelander S, Nerdrum T, Pedersen V, M lbjerg C. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. Acta Psychiat Scand. 1991;84:14-21.10.1111/j.1600-0447.1991.tb01414.xWistedtBKoskinenTThelanderSNerdrumTPedersenV, MlbjergCZuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre studyActa Psychiat Scand1991841421Open DOISearch in Google Scholar
Eklund K, Forsman A. Minimal effective dose and relapse—double-blind trial: haloperidol decanoate vs. placebo. Clin Neuropharmacol. 1991; 14 (Suppl. 2): S7-12; discussion S12-15.EklundKForsmanAMinimal effective dose and relapse—double-blind trial: haloperidol decanoate vs. placeboClin Neuropharmacol199114Suppl. 2S7-12S12-15Search in Google Scholar
Dencker SJ, Lepp M, Malm U. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. I. A one year double-blind study of clopenthixol decanoate and flupenthixol palmitate. Acta Psychiat Scand Suppl. 1980; 279:10-28.DenckerSJLeppMMalmUClopenthixol and flupenthixol depot preparations in outpatient schizophrenicsI. A one year double-blind study of clopenthixol decanoate and flupenthixol palmitate. Acta Psychiat Scand Suppl19802791028Search in Google Scholar
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012; 379:2063-71.2256060710.1016/S0140-6736(12)60239-6LeuchtSTardyMKomossaKHeresSKisslingWSalantiGet alAntipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysisLancet2012379206371Search in Google Scholar
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382:951-62.2381001910.1016/S0140-6736(13)60733-3LeuchtSCiprianiASpineliLMavridisDOreyDRichterFet alComparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisLancet201338295162Search in Google Scholar
Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophrenia Bull. 2014; 40:192-213.10.1093/schbul/sbs150KishimotoTRobenzadehALeuchtCLeuchtSWatanabeKMimuraMet alLong-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trialsSchizophrenia Bull201440192213388528923256986Open DOISearch in Google Scholar
Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC. 2010; 10:54.WoodsBSHawkinsNScottDANetwork meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorialBMC2010105410.1186/1471-2288-10-54290650020537177Search in Google Scholar
